Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludarabine vs Fludarabine + Cyclophosphamide in First-Line Advanced CLL
NCT00276848Phase 3Completed
- Sponsor
- German CLL Study Group
- Start
- Jul 1999
- Primary completion
- Jul 2003
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial of cyclophosphamide in chronic lymphocytic leukemia (CLL) (2 arms), sponsored by German CLL Study Group. Primary endpoints: Progression-Free Survival at 18 months, Overall Survival at 18 months and 1 more. Started Jul 1999; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00276848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00276848.